Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 15 - Drugs for genital or sexual disorders; Contraceptives
Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635)
10/2003
10/30/2003WO2003004501A3 (hetero) aryl substituted benzofurans as 5-ht ligands
10/30/2003WO2002098391A3 Process for preparing granular compositions
10/30/2003WO2002072106A3 Combined method for treating hormono-dependent disorders with exemestane
10/30/2003WO2002070741A3 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
10/30/2003WO2002056903A3 Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
10/30/2003WO2002034783A3 Transmembrane proteins
10/30/2003US20030204071 109 human secreted proteins
10/30/2003US20030204052 Comprises polypeptide for treatment and prevention of autoimmune, cancer, inflammatory, nervous system, cardiomyopathy and atherosclerotic disorders
10/30/2003US20030203957 Selected fused pyrrolocarbazoles
10/30/2003US20030203933 Novel curcumin analogues and uses thereof
10/30/2003US20030203926 For treatment of inflammatory or autoimmune condition, viral infection, cancer
10/30/2003US20030203922 Substituted amine derivatives and methods of use
10/30/2003US20030203902 A 2-hydroxy-2-trifluoromethyl-valeroylamino benzotriazole, or benzo(1,2,5)thiadiazole, or benzo(1,2,5)oxadiazole derivatives; contraceptive agents, for treating endometriosis, gynecological disorders, male birth control
10/30/2003US20030203890 Administering a neurotrophic compound 2-pyrrolidinecarboxylate derivatives after prostate surgery as well as erectile dysfunction
10/30/2003US20030203855 17-Aryl linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase
10/30/2003US20030203396 Human galactosyltransferases
10/30/2003US20030203055 Administering a selective norepinephrine norepinephrine-serotonin reuptake inhibitor, e.g., milnacipran, that is not a tricylcic antidepressant; gastrointestinal and urogenital disorders; analgesics
10/30/2003US20030203052 Superoxide dismutase-containing cucumber extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance can be used by the topical or oral route; antiallergens; sunscreen agents; foods; drugs; cosmetics
10/30/2003US20030202939 Forming oxygen free radicals; destroying tumor, cancer
10/30/2003EP1496982A2 Solid forms of salts with tyrosine kinase activity
10/30/2003CA2770411A1 Aerosol containing a particulate active substance
10/30/2003CA2483311A1 Modulators of hedgehog signaling pathways, compositions and uses related thereto
10/30/2003CA2482037A1 Condom
10/30/2003CA2480451A1 New 2-substituted -1,3-thiazole compounds
10/30/2003CA2480325A1 Solid forms of salts with tyrosine kinase activity
10/29/2003EP1356092A2 Compositions and methods for the therapy and diagnosis of ovarian cancer
10/29/2003EP1356043A2 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
10/29/2003EP1356042A2 Carbohydrate-associated proteins
10/29/2003EP1356028A2 Protein modification and maintenance molecules
10/29/2003EP1355921A2 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
10/29/2003EP1355905A1 Pyrazole compounds useful as protein kinase inhibitors
10/29/2003EP1355903A1 Pyrazole derivatives against tgf overexpression
10/29/2003EP1355902A1 Sulfonamide compounds, their preparation and use
10/29/2003EP1355893A2 Antiangiogenic compounds and an assay for inhibitors of cell invasion
10/29/2003EP1355650A1 New combination of active ingredients containing alfuzosine and apomorphine
10/29/2003EP1355649A2 Pharmaceutical formulation containing pyrazolo 4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
10/29/2003EP1355647A2 The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers
10/29/2003EP1355645A2 Method for treating fibrotic diseases or other indications iiic
10/29/2003EP1355639A2 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
10/29/2003EP1355638A2 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
10/29/2003EP1355631A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
10/29/2003EP1235787B1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS
10/29/2003EP1169316B9 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
10/29/2003EP1147112B1 Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
10/29/2003EP1082129B1 Method for the treatment of fertility disorders
10/29/2003EP0831822B1 The use of calcium channel antagonists for treating cardiac, renal and gastrointestinal disorders and hypertension
10/29/2003CN1452628A 4-halogenated 17-methylene steroids, method for production thereof and pharmaceutical compositions contg. these compounds
10/29/2003CN1452622A Piperzine devivs.
10/29/2003CN1452497A Combinations of SSRI and estrogenic agents
10/29/2003CN1452489A Praziquantel composition for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
10/29/2003CN1452483A IL-8 receptor antagonists
10/29/2003CN1451661A European verbena herb extract, and preparing process and use thereof
10/29/2003CN1451426A Medicinal composition and use thereof
10/29/2003CN1451424A Preparation of catechu suppository
10/29/2003CN1451410A Formulation of medicine and preparing process thereof
10/28/2003US6638957 Inhibition of 1-deoxy-D-xylulose-5-phosphate metabolic pathway
10/28/2003US6638948 A free-flowing, amorphous paroxetine hydrochloride composition suitable as a therapeutic agent for premature ejaculation can be prepared by dissolving paroxetine free base in a hydrochloric acid-ethanol solution followed by
10/28/2003US6638942 Spiro-indolines as Y5 receptor antagonists
10/28/2003US6638727 Intraductally administering an estrogen activity modulator
10/28/2003US6638499 A nitrogen group containing linkage which is attached one end with a polyoxyalkylene glycol polymer and other end is coupled with a drug; useful for drug delivery
10/28/2003CA2283939C Non-antigenic branched polymer conjugates
10/28/2003CA2253796C Inhibition of matrix metalloproteases by acetylene containing compounds
10/23/2003WO2003087832A2 Diagnosis of carcinoma using raigi polypeptides
10/23/2003WO2003087411A1 Method to inhibit cell growth using oligonucleotides
10/23/2003WO2003087151A1 A sperm polypeptide
10/23/2003WO2003087108A2 Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses
10/23/2003WO2003087086A2 Substituted indoles
10/23/2003WO2003087062A2 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
10/23/2003WO2003087061A1 Pyrazole compounds as anti-inflammatory and analgesic agents
10/23/2003WO2003087042A1 Occlusive composition comprising a poly (2-cyanoacrylate) monomer
10/23/2003WO2003087040A2 Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
10/23/2003WO2003086464A1 Preventives/remedies for hotflash
10/23/2003WO2003086459A1 Methods of treatement using ctla-4 antibodies
10/23/2003WO2003086458A1 Recombinant anti-interleukin-9 antibodies
10/23/2003WO2003086427A1 Topical formulation for dredging or interupting milk without pain and its process
10/23/2003WO2003086390A1 Imidazole compounds as anti-inflammatory and analgesic agents
10/23/2003WO2003086373A1 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
10/23/2003WO2003086372A2 Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction
10/23/2003WO2003086354A1 Nanoparticulate megestrol formulations
10/23/2003WO2003086351A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
10/23/2003WO2003086325A2 Cyanamides useful as reversible inhibitors of cysteine proteases
10/23/2003WO2003086317A2 Protein a compositions and methods of use
10/23/2003WO2003086315A2 Tyrosine kinase inhibitors
10/23/2003WO2003086314A2 Tyrosine kinase inhibitors
10/23/2003WO2003086311A2 Methods for treating tweak-related conditions
10/23/2003WO2003086306A2 5ht2c receptor modulators
10/23/2003WO2003086298A2 Use of interleukin-19 to treat ovarian cancer
10/23/2003WO2003086080A1 Method and composition for improving fertility health in female and male animals and humans
10/23/2003WO2003027094A3 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
10/23/2003WO2003005954A3 Methods and materials for the treatment of testosterone deficiency in men
10/23/2003WO2002081521A8 Osteoprotegerin in milk
10/23/2003WO2002046384A3 Kinases and phosphatases sequences, and use thereof
10/23/2003WO2001055337A9 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
10/23/2003WO2001000812A8 22012, a novel human carboxypeptidase
10/23/2003WO2001000811A8 17867, a novel human aminopeptidase
10/23/2003US20030199701 Treating under hydrolyzing conditions a hydantoin compound to form an alpha-amino acid derivative
10/23/2003US20030199569 Pyrrolidine derivatives
10/23/2003US20030199562 Substituted benzoxazoles as estrogenic agents
10/23/2003US20030199555 Indoline compounds and to pharmaceutical compositions containing them
10/23/2003US20030199525 Kinase inhibitors
1 ... 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 ... 557